Axsome Therapeutics Announces Positive Outcome of Interim Analysis of ADVANCE-1 Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
10 déc. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
IDMC recommends continuation of trial evaluating AXS-05 versus placebo in Alzheimer’s disease agitation IDMC recommends no further enrollment to single-agent bupropion arm NEW YORK, Dec. 10, 2018 ...
Axsome Therapeutics Expands Loan Agreement with Silicon Valley Bank Providing Additional Growth Capital Related to AXS-12 Product Candidate
27 nov. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Participate in 2018 Global Mizuho Investor Conference
19 nov. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder
14 nov. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Reports Third Quarter 2018 Financial Results and Provides Business Update
09 nov. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Final Phase 3 results of AXS-05 in treatment resistant depression now anticipated in 1Q 2019 Final Phase 2 results of AXS-05 in major depressive disorder anticipated around year-end 2018 Phase 2/3...
Axsome Therapeutics to Report Third Quarter 2018 Financial Results on November 9, 2018
01 nov. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Axsome to host conference call and webcast on Friday, November 9, 2018 at 8:00 AM Eastern Time NEW YORK, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage...
Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Alzheimer’s Disease Agitation
18 oct. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics Receives FDA Orphan Drug Designation for AXS-12 for the Treatment of Narcolepsy
17 oct. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, Oct. 17, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
Axsome Therapeutics to Host Call Today with Key Opinion Leader Focusing on AXS-12 and Unmet Needs in Narcolepsy
16 oct. 2018 07h05 HE
|
Axsome Therapeutics, Inc.
Conference call and webcast to be held today at 8:00 AM Eastern Time NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company...
Axsome Therapeutics Announces AXS-12 for the Treatment of Narcolepsy
16 oct. 2018 07h00 HE
|
Axsome Therapeutics, Inc.
Narcolepsy is a debilitating, orphan neurological condition with limited treatment options Phase 2 trial set to start in 4Q 2018 with results anticipated in 1H 2019 Conference call and webcast...